Ezetimibe 10 mg
There has been a change from your Ezetrol (ezetimibe) tablets, supplied by Merck, Sharpe and Dohme (NZ) Ltd, to Ezemibe (ezetimibe) tablets, supplied by Mylan NZ Ltd.
Recently a decision was made to change from the Ezetrol brand to the Ezemibe brand, which has the same active ingredient, ezetimibe. This means that from 1 November 2015, only the Ezemibe brand of ezetimibe will be funded when prescribed by your doctor.
What is changing?
The funded brand of ezetimibe will change from Ezetrol to Ezemibe.
When will the change happen?
- From 1 June 2015 the Ezemibe brand will be listed on the Pharmaceutical Schedule.
- From 1 August 2015 a part payment may be required for Ezetrol unless you have already changed to the Ezemibe brand.
- From 1 November 2015, only Ezemibe will be available and fully funded.
Will the tablets or pack look different?
Because they are made by a different supplier, the Ezemibe tablets and pack look a little different to your previous medication.
Will the medicine work the same?
Your medicine itself is not changing, only the brand. The newly funded tablets contain the same amount of active ingredient, ezetimibe. This means that the effect you experience when taking Ezemibe, should be the same as with Ezetrol.
Medsafe, the agency that approves medicine for use in New Zealand, approved Ezemibe after carefully considering its safety and effectiveness. Medsafe considered Ezemibe should have the same effect as Ezetrol.
You shouldn’t notice any difference in how you feel after taking Ezemibe. If you do notice any major changes or side effects, please talk with your doctor about it.
Will my current brand be available after 1 November 2015?
If you would prefer to continue taking the Ezetrol brand after 1 November 2015, all the costs of purchasing it will have to be met by you.
The availability and price of Ezetrol after 1 June 2015 will be at the discretion of the pharmaceutical supplier (Merck Sharpe Dohme).
Will the new brand cost me any more?
Other than the usual patient co-payment, there will be no extra cost to you for Ezemibe.
Why has this change happened?
Significant savings are associated with the move to the Ezemibe brand of ezetimibe tablets. This means that more money can be freed up to fund other medicines to treat other people in our communities.
Where can I get more information?
Please phone the PHARMAC helpline, 0800 66 00 50 (between 9 am and 4 pm weekdays).
You can also email firstname.lastname@example.org with your queries and/or comments.
Your doctor and pharmacist will also help guide you during the changeover period.
Last updated: 4 July 2016